Aurinia Pharmaceuticals Inc. achieved record Lupkynis sales of $66.6M in Q2 while managing cash flow. Click for insights on ...

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: ...

Cash runway into Q2 2027, with cash, cash equivalents, and investments of $142.4 million as of June 30, 2025 ...

Five key updates to the language describing Sjögren disease offer clearer communication for patients, and may improve research.

Crispr Therapeutics (($CRSP)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled ‘A Phase 1 Dose ...

Experiencing persistent joint pain, fatigue or unexplained rashes? These could be signs of an autoimmune condition.

High adherence to the Mediterranean diet is associated with a reduced risk for SLE, with the relationship partially mediated by certain liver and kidney function biomarkers.

DelveInsight's TYK2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

For the second quarter, total revenues increased 9% to $9.2 billion in comparison to the second quarter of 2024. Product sales grew 9%, driven by 13% volume g ...

Obinutuzumab, a B-cell depleting therapy, is being explored for reducing lupus nephritis risks, such as flare.

Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development ...